证券代码：300204 证券简称：舒泰神 公告编号：2025-036 舒泰神（北京）生物制药股份有限公司 关于公司药品生产许可证变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 舒泰神（北京）生物制药股份有限公司（以下简称"公司"）于近期取得了 北京市药品监督管理局（以下简称"市药监局"）换发的药品生产许可证，同意 公司"北京市北京经济技术开发区经海二路 36 号"地址项下的"原液四车间： 原液四车间生产线、冻干车间：冻干粉针生产线"接受江苏贝捷泰生物科技有限 公司的注射用 STSP-0601 的委托生产。《药品生产许可证》有效期至 2025 年 12 月 07 日，分类码增加 Cs（仅限注册申报使用）。本次委托生产品种待持有人取 得药品批准证明文件并通过药品 GMP 符合性检查后方可正式生产。变更后的《药 品生产许可证》具体内容如下： 一、《药品生产许可证》主要情况 企业名称：舒泰神（北京）生物制药股份有限公司 社会信用代码：911100007423131451 注册地址：北京市北京经济技术开发区经海二路 36 号 法定代表人：周志文 企业负责人： ...

作者 | 哥吉拉 数据支持 | 勾股大数 据（www.gogudata.com） 5月29日，A股主要指数高开高走，截至收盘，沪指涨0.7%报3363点，深证成指涨1.24%，创业板指涨1.37%。全市场近4500股上涨，逾百 股涨停。 板块方面，金融科技、创新药、互联网、半导体等热门板块表现强势，市场情绪相比近日明显提振。 其中，创新药是涨幅最明显的板块之一，睿智医药、舒泰神、益方生物强势斩获20CM涨停，另有十多家医药股涨幅均超过10%，堪称又一轮 暴涨潮。 | 代码 | 名称 | 现价 | 1 9 mm a lond a rither more an a many 143 1994 (310 1 涨跌幅▼ | 年初至今涨跌幅 | 总市值1 | | --- | --- | --- | --- | --- | --- | | 300149 | 睿智医药 | 8.56 c | 20.06% | 33.33% | 43亿 | | 300204 | 舒泰神 | 23.04 c | 20.00% | 210.93% | 110亿 | | 688382 | 益元生物-U | 29.10 c | 20.00% | 11 ...

Market Overview - The A-share market saw a strong rise with the three major indices up, including the Shanghai Composite Index increasing by 0.7% to 3363.45 points, the Shenzhen Component rising by 1.24% to 10127.2 points, and the ChiNext Index up by 1.37% to 2012.55 points. The North Star 50 Index surged by 2.73% [1] - Total trading volume in the Shanghai, Shenzhen, and North exchanges reached 121.36 billion yuan, an increase of nearly 18 billion yuan compared to the previous day [1] Semiconductor Sector - The semiconductor sector experienced a significant rally, with stocks like GCL-Poly and Guangliwei both hitting the 20% limit up. Other notable performers included Huada Jiutian, which rose nearly 15%, and Taiji Co., which increased over 9% [5][6] - Reports indicated that the U.S. government is requesting local companies to stop exporting software related to semiconductor design technology to China, affecting major companies in the Electronic Design Automation (EDA) market [7] Innovative Drug Sector - The innovative drug concept saw a substantial increase, with stocks such as Ruizhi Pharmaceutical, Yifang Bio, and Shutaishen all hitting the 20% limit up. Changshan Pharmaceutical rose over 15%, reaching new highs [9][11] - Shutaishen announced that it received approval for clinical trials of its STSA-1002 injection for acute respiratory distress syndrome (ARDS), marking a significant step in its drug development [12] Data Element Sector - The data element concept showed strong performance, with stocks like Lakala, Xiongdi Technology, and Tianyang Technology all hitting the 20% limit up. Youbuxun rose over 14% [15][16] - The National Data Bureau announced the launch of the "Data Element ×" competition aimed at promoting the use of public and enterprise data, which is expected to enhance the economic and social development through better data application [17]

Market Overview - A-shares experienced a rebound on May 29, with the Shanghai Composite Index rising by 0.72%, the Shenzhen Component Index increasing by 1.12%, and the ChiNext Index up by 1.16% [1][2]. Sector Performance - The digital currency and fintech sectors saw significant gains, while sectors such as gold and jewelry, air transportation, and food processing faced declines [2][3]. - Notable sector performances included: - Digital currency: +6.56% - Fintech: +5.48% - Innovative drugs: +20% for Shuyou Shen [3][7]. Notable Stocks - In the Hong Kong market, the Hang Seng Technology Index rose by 1.64%, with stocks like Xpeng Motors (+6.08%), Meituan (+4.64%), and Trip.com (+3.81%) leading the gains [4][5]. - Digital currency stocks surged, with companies like Sifang Jingchuang, Xiongdai Technology, and Tianyang Technology hitting the daily limit of 20% [5]. - Innovative drug stocks also performed well, with Shuyou Shen reaching a three-year high [7][9]. Regulatory Developments - The U.S. Congress is advancing two key stablecoin legislations, while Hong Kong's Legislative Council has passed a stablecoin bill, establishing a licensing system for fiat-backed stablecoin issuers [10].

Market Overview - The three major A-share indices rose collectively in the morning session, with the Shanghai Composite Index up 0.72%, the Shenzhen Component Index up 1.12%, and the ChiNext Index up 1.16% [1] - The total market turnover reached 759.4 billion yuan, an increase of 91.6 billion yuan compared to the previous day, with over 4,400 stocks rising [1] Sector Performance - The leading sectors included autonomous driving, innovative pharmaceuticals, and cross-border payments, while precious metals and food sectors saw declines [2] - Notable stocks in the autonomous driving sector included Yunnei Power and Tongda Electric, both achieving four consecutive trading limit increases [2] - The innovative pharmaceutical sector also performed well, with stocks like Ruizhi Pharmaceutical and Shutaishen hitting trading limits [2] Notable Stocks and Trends - The stock of Shangwei Co. achieved six consecutive trading limit increases, indicating strong investor interest [4] - Stocks such as Yunnei Power and Tongda Electric have shown significant momentum with four consecutive trading limit increases [5] - The innovative pharmaceutical company Shutaishen reported promising clinical trial results for its STSA-1002 injection, showing a significant reduction in mortality rates compared to the control group [10] Strategic Developments - A strategic cooperation framework agreement was signed between Xiaoma Zhixing and Guangzhou Public Transport Group to collaborate in the fields of autonomous vehicles and logistics services [11] - The market is also reacting to legislative developments regarding stablecoins in the U.S. and Hong Kong, which may impact the cross-border payment sector [13]

Market Overview - A-shares opened higher collectively, with the Shanghai Composite Index up 0.25% to 3348.16, the Shenzhen Component Index up 0.49% to 10052.64, and the ChiNext Index up 0.60% to 1997.29 [1] - Hong Kong's Hang Seng Index rose 0.44% to 23359.74, while the Hang Seng Tech Index increased by 0.70% to 5210.92 [2][3] Sector Performance - The EDA concept stocks surged, with companies like Gai Lun Electronics hitting the daily limit up of 20%, and others like Guangliwei and Huada Jiutian rising over 15% [4][7] - The nuclear power sector showed strong activity, with companies such as Shangwei Co. achieving six consecutive trading limits, and others like Hezhu Intelligent and Zhongchao Holdings rising by 5% [8] Commodity and Bond Market - Domestic commodity futures mostly declined, with coking coal dropping over 2% [1][12] - The bond market saw a decline across the board, with the 30-year main contract down 0.31% and the 10-year main contract down 0.13% [9] Innovation Drug Sector - The innovative drug sector strengthened, with Shutaishen hitting a daily limit up of 20%, marking a three-year high, and other companies like Yifang Bio and Yipin Hong also seeing significant gains [4][6]

暗盘资金正涌入这些股票，点击速看>>> 创新药板块短线拉升，舒泰神（300204）20cm涨停，益方生物、一品红（300723）、华纳药厂、微芯 生物、智翔金泰等纷纷走高。 ...

细胞免疫治疗板块短线拉升，舒泰神（300204）涨超10%，雪榕生物（300511）、荣昌生物、金域医学 （603882）、莱美药业（300006）、和元生物等跟涨。 暗盘资金正涌入这些股票，点击速看>>> ...

证券代码：300204 证券简称：舒泰神 公告编号：2025-035 舒泰神（北京）生物制药股份有限公司 关于 STSA-1002 注射液（急性呼吸窘迫综合征适应症） 获得 Ib/II 期临床试验研究初步结果的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 舒泰神（北京）生物制药股份有限公司（以下简称"舒泰神"或"公司"） 于 2023 年 03 月收到国家药品监督管理局签发的 STSA-1002 注射液用于急性呼 吸窘迫综合征（ARDS）适应症的《药物临床试验批准通知书》（CXSL2200630）， 同意本品开展用于急性呼吸窘迫综合征（ARDS）的临床试验。2023 年 12 月， STSA-1002 注射液完成针对急性呼吸窘迫综合征（ARDS）Ib/II 期临床试验的首 例受试者给药。 近日，STSA-1002 注射液已结束针对急性呼吸窘迫综合征（ARDS）Ib/II 期 临床试验入组，完成数据库清理、盲态数据审核、揭盲，并收到顶线数据（Top- line Data）初步统计分析结果。本次 STSA-1002 注射液（急性呼吸窘迫综合征适 应症）获得 ...

证券代码：300204 证券简称：舒泰神 公告编号：2025-034 舒泰神（北京）生物制药股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、舒泰神（北京）生物制药股份有限公司股票交易连续三个交易日（2025 年05月23日、2025年05月26日、2025年05月27日）收盘价格涨幅偏离值累计超过 30%，根据《深圳证券交易所交易规则》等相关规定，属于股票交易异常波动的 情况。 2、经公司董事会核实，截至本公告披露日，公司、控股股东和实际控制人 不存在关于本公司的应披露而未披露的重大事项，在股票异常波动期间不存在买 卖公司股票的行为。 5、经核查，公司、控股股东和实际控制人在股票异常波动期间不存在买卖 公司股票的行为。 6、异动期间，公司不存在违反公平信息披露规定的其他情形。 3、风险提示：公司多个在研项目属于创新型生物制品。创新生物医药具有 高科技、高风险、高附加值的特点，从研制、临床试验、报批到投产的周期长、 环节多，容易受到技术、审批、政策等诸多因素影响，面临临床试验进度可能不 如预期、临床试 ...